Diebold Nixdorf, Incorporated
DBD · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $2 |
| - Cash | $0 | $1 | $0 | $0 |
| + Debt | $1 | $1 | $3 | $2 |
| Enterprise Value | $2 | $3 | $4 | $4 |
| Revenue | $4 | $4 | $3 | $4 |
| % Growth | -0.2% | 8.7% | -11.4% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 24.5% | 23.3% | 21.9% | 26.7% |
| EBITDA | $0 | $0 | -$0 | $0 |
| % Margin | 8.9% | 7.3% | -3.3% | 7.5% |
| Net Income | -$0 | $1 | -$1 | -$0 |
| % Margin | -0.4% | 36.6% | -16.8% | -2% |
| EPS Diluted | -0.44 | 21.38 | -7.44 | -1 |
| % Growth | -102.1% | 387.4% | -644% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | $0 |